Novel Genetic Variants of ALG6 and GALNTL4 of the Glycosylation Pathway Predict Cutaneous Melanoma-Specific Survival
Open Access
Abstract
Because aberrant glycosylation is known to play a role in the progression of melanoma, we hypothesize that genetic variants of glycosylation pathway genes are associated with the survival of cutaneous melanoma (CM) patients. To test this hypothesis, we used a Cox proportional hazards regression model in a single-locus analysis to evaluate associations between 34,096 genetic variants of 227 glycosylation pathway genes and CM disease-specific survival (CMSS) using genotyping data from two previously published genome-wide association studies. The discovery dataset included 858 CM patients with 95 deaths from The University of Texas MD Anderson Cancer Center, and the replication dataset included 409 CM patients with 48 deaths from Harvard University nurse/physician cohorts. In the multivariable Cox regression analysis, we found that two novel single-nucleotide polymorphisms (SNPs) (ALG6 rs10889417 G>A and GALNTL4 rs12270446 G>C) predicted CMSS, with an adjusted hazards ratios of 0.60 (95% confidence interval = 0.44–0.83 and p = 0.002) and 0.66 (0.52–0.84 and 0.004), respectively. Subsequent expression quantitative trait loci (eQTL) analysis revealed that ALG6 rs10889417 was associated with mRNA expression levels in the cultured skin fibroblasts and whole blood cells and that GALNTL4 rs12270446 was associated with mRNA expression levels in the skin tissues (all p < 0.05). Our findings suggest that, once validated by other large patient cohorts, these two novel SNPs in the glycosylation pathway genes may be useful prognostic biomarkers for CMSS, likely through modulating their gene expression.Keywords
Funding Information
- National Institutes of Health/National Cancer Institute (R01 CA100264, 2P50CA093459 and R01CA133996, R01 CA49449, P01 CA87969, UM1 CA186107 and UM1 CA167552)
- Duke Cancer Institute as part of the P30 Cancer Centre Support Grant (NIH CA014236)
- National Natural Science Foundation of China (81573072)
This publication has 46 references indexed in Scilit:
- Aberrant Glycosylation in Cancer: A Novel Molecular Mechanism Controlling MetastasisCancer Cell, 2017
- A Systems Biology Approach Identifies FUT8 as a Driver of Melanoma MetastasisCancer Cell, 2017
- Evaluating the association of multiple single nucleotide polymorphisms with response to gemcitabine and platinum combination chemotherapy in urothelial carcinoma of the bladderInt. Journal of Clinical Pharmacology and Therapeutics, 2017
- Clinical Evaluation of Cisplatin Sensitivity of Germline Polymorphisms in Neoadjuvant Chemotherapy for Urothelial CancerClinical Genitourinary Cancer, 2016
- Clinical utility gene card for: ALG1 defective congenital disorder of glycosylationEuropean Journal of Human Genetics, 2015
- The Genetic Landscape of Clinical Resistance to RAF Inhibition in Metastatic MelanomaCancer Discovery, 2014
- Genome-wide association study identifies a new melanoma susceptibility locus at 1q21.3Nature Genetics, 2011
- A Versatile Gene-Based Test for Genome-wide Association StudiesThe American Journal of Human Genetics, 2010
- A genome-wide shRNA screen identifies GAS1 as a novel melanoma metastasis suppressor geneGenes & Development, 2008
- Inhibition of N-linked glycosylation using tunicamycin causes cell death in malignant cells: role of down-regulation of the insulin-like growth factor 1 receptor in induction of apoptosis.1997